A Study of JNJ-77474462 (Bermekimab) in Healthy Chinese Participants

Janssen Research & Development, LLC

Overview

The purpose of this study is to assess the pharmacokinetics (PK) of JNJ-77474462 following single ascending dose subcutaneous (SC) administration to healthy Chinese participants.

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Conditions

Healthy

Interventions

JNJ-77474462DRUG

JNJ-77474462 will be administered subcutaneously.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Have a body mass index (BMI) between 18 and 27.9 kilograms per meter square (kg/m\^2) (BMI = weight/height\^2), inclusive, and a body weight of between 50 to 90 kg, inclusive * Otherwise healthy on the basis of physical examination, medical history, vital signs, and 12-lead electrocardiogram (ECG) performed at screening and Day -2 to -1. Any abnormalities must be considered not clinically significant and this determination must be recorded in the participant's source documents and initialed by the investigator * A female of childbearing potential must have a negative pregnancy test at screening and on Day -2 to -1 * Must have 3 quadrants on the abdomen where the skin is not tender, bruised, red, scaly, hardened, or tattooed for subcutaneous (SC) administration * Must be a nonsmoker or agree to smoke no more than 10 cigarettes or 2 cigars per day throughout the study Exclusion Criteria: * History of any clinically significant medical illness or medical disorders the investigator considers should exclude the participant, including (but not limited to), neuromuscular, hematological disease, immune deficiency state, respiratory disease, hepatic or gastrointestinal disease, neurological or psychiatric disease, ophthalmological disorders, endocrine, neoplastic disease, renal or urinary tract diseases, or dermatological disease * History of drug or alcohol abuse according to Diagnostic and Statistical Manual of Mental Disorders (5th edition) (DSM-V) criteria within 12 months before Screening or positive test result(s) for alcohol or drugs of abuse (including morphine, ketamine, tetrahydrocannabinolic acid, methamphetamine, dimethylene dioxoamphetamine, cocaine) at Screening and Day -2 to -1 * Have a history of active granulomatous infection (including histoplasmosis or coccidioidomycosis), nontuberculous mycobacterial infection or opportunistic infection (including pneumocystosis, aspergillosis, and disseminated herpes zoster defined as zoster with central nervous system involvement or zoster spreading to more than 2 adjacent dermatomes) * Has a chest radiograph within 3 months before the first administration of study intervention that shows an abnormality suggestive of a malignancy or current active infection, including tuberculosis (TB). A chest computerized tomography (CT) scan is also acceptable if already available or obtained outside of the study protocol * Has tested positive for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and treponema pallidum-specific antibody

Outcomes

Primary Outcomes

Maximum Observed Serum Concentration (Cmax) of JNJ-77474462

Cmax is defined as the maximum observed serum concentration of JNJ-77474462.

Time frame: Up to Day 85

Time to Reach Maximum Observed Serum Concentration (Tmax) of JNJ-77474462

Tmax is defined as the time to reach maximum observed serum concentration of JNJ-77474462.

Time frame: Up to Day 85

Area Under the Serum Concentration Versus Time Curve from Time Zero to Infinity (AUC [0-Infinity]) of JNJ-77474462

AUC (0-infinity) is defined as the area under the serum concentration of JNJ-77474462 versus time curve from time zero to infinity with extrapolation of the terminal phase.

Time frame: Up to Day 85

Area Under the Serum Concentration Versus Time Curve from Time Zero to the Time Corresponding to the Last Quantifiable Concentration (AUC [0-Last]) of JNJ-77474462

AUC (0-Last) is defined as the area under the serum concentration of JNJ-77474462 versus time curve from time zero to the time corresponding to the last quantifiable concentration.

Time frame: Up to Day 85

Terminal Half-life (T1/2) of JNJ-77474462

T1/2 will be reported. T1/2 is defined as the terminal half-life of JNJ-77474462.

Time frame: Up to Day 85

Apparent Total Systemic Clearance after Extravascular Administration (CL/F) of JNJ-77474462

CL/F is defined as the apparent total systemic clearance after extravascular administration of JNJ-77474462.

Time frame: Up to Day 85

Apparent Volume of Distribution Based on Terminal Phase After Extravascular Administration (Vz/F) of JNJ-77474462

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Percentage of Participants with Treatment-emergent Adverse Events (TEAEs) by Severity

Percentage of participants with TEAEs by severity will be reported. An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Any AE occurring at or after the initial administration of study intervention through Day 85 is considered to be treatment-emergent. Severity will be assessed based on the following categories: a) Mild: Awareness of symptoms that are easily tolerated, causing minimal discomfort and not interfering with everyday activities, b) Moderate: Sufficient discomfort is present to cause interference with normal activity and c) Severe: Extreme distress, causing significant impairment of functioning or incapacitation. Prevents normal everyday activities.

Time frame: Up to Day 85

Percentage of Participants with Serious Adverse Events (SAEs)

Percentage of participants with SAEs will be reported. A SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect, is suspected transmission of any infectious agent via a medicinal product, is medically important to prevent one of the outcomes listed above.

Time frame: Up to Day 85

Number of Participants with Clinically Significant Changes in Vital Signs

Number of participants with clinically significant changes in vital signs (temperature, pulse/heart rate, respiratory rate and blood pressure) will be reported.

Time frame: Up to Day 85

Number of Participants with Clinically Significant Changes in Electrocardiograms (ECGs)

Number of participants with clinically significant changes in ECGs will be reported.

Time frame: Up to Day 85

Number of Participants with Clinically Significant Changes in Hematology Parameters

Number of participants with clinically significant changes in hematology parameters will be reported.

Time frame: Up to Day 85

Number of Participants with Clinically Significant Changes in Chemistry Parameters

Number of participants with clinically significant changes in chemistry parameters will be reported.

Time frame: Up to Day 85

Number of Participants with Clinically Significant Changes in Urinalysis

Number of participants with clinically significant changes in urinalysis will be reported.

Time frame: Up to Day 85

Number of Participants with Presence of Antibodies to JNJ-77474462

Number of participants with presence of antibodies to JNJ-77474462 will be reported. The detection and characterization of antibodies to JNJ-77474462 will be performed using a validated drug-tolerant method.

Time frame: Up to Day 85